石四药集团（02005）3月28日公布2024年度业绩，公司实现净利润10.61亿港元，下降19.5%；销售收入57.73亿港元，减少10.7%。毛利率下滑5.6个百分点至50.4%。
业绩下滑主要受非PVC软袋输液及安瓿注射液收益减少影响。尽管静脉输液和安瓿注射液销量增长6.7%至20.36亿瓶（袋），但受政策性和市场性叠加因素影响销售额仍下降7.6%。原料药销售额7.85亿港元，减少11.7%。
业务亮点方面，口服制剂收入5.02亿港元，同比增长4.9%；医用材料业务收入1.88亿港元，增长16.4%。2024年公司完成44个通用名56个品规的上市准入。
公司表示，面对行业挑战，已积极调整营销策略，优化产品结构，并参与多项药品招标活动，未来将重点开拓高附加值产品市场。集团将继续聚焦高附加值产品的市场开拓，以推动未来的业务增长。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.